2023
Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life
Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco J, Washington S, Renzulli J, Sprenkle P, Kim I, Leapman M. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. Urologic Oncology Seminars And Original Investigations 2023, 42: 28.e9-28.e20. PMID: 38161105, DOI: 10.1016/j.urolonc.2023.10.005.Peer-Reviewed Original ResearchLethal prostate cancerSociodemographic factorsAdvanced CaPAdvanced diseaseYounger patientsProstate cancerHigher oddsAdvanced stageProstate-specific antigen (PSA) screeningCharacteristics of patientsNational Cancer DatabaseRetrospective cohort studySubset of patientsPatient sociodemographic factorsMultivariable logistic regressionPatients' health insuranceHighest income quartileCohort studyAdvanced cancerAntigen screeningMean ageInsurance statusCancer DatabaseCaP screeningSociodemographic disparitiesAssociation between sociodemographic factors and diagnosis of advanced prostate cancer in early life.
Smani S, Novosel M, Jeong F, Marks V, Sprenkle P, Leapman M. Association between sociodemographic factors and diagnosis of advanced prostate cancer in early life. Journal Of Clinical Oncology 2023, 41: 32-32. DOI: 10.1200/jco.2023.41.6_suppl.32.Peer-Reviewed Original ResearchAdvanced prostate cancerProstate cancerProstate cancer diagnosisSociodemographic factorsAdvanced diseaseYounger patientsNational Cancer DatabaseCancer diagnosisCharacteristics of patientsRetrospective cohort studySubset of patientsLethal prostate cancerMultivariable logistic regressionEarly prostate cancerHighest income quintileCohort studyAdvanced cancerInsurance statusCancer DatabaseSociodemographic disparitiesInclusion criteriaWhite raceGreater oddsPatientsAdvanced stage
2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatientsChange in facility-level share of Medicaid patients with cancer following implementation of the affordable care act.
Buck M, Demkowicz P, Nie J, Marks V, Salazar M, Kenney P, Boffa D, Leapman M. Change in facility-level share of Medicaid patients with cancer following implementation of the affordable care act. Journal Of Clinical Oncology 2021, 39: e18543-e18543. DOI: 10.1200/jco.2021.39.15_suppl.e18543.Peer-Reviewed Original ResearchProportion of MedicaidAffordable Care ActMedicaid patientsMedicaid expansionFacility-level changesFacility-level policiesNational Cancer DatabasePrimary study endpointProportion of patientsInsurance coverageMultivariable logistic regressionExpansion statesCare ActFacility-level factorsMedicaid expansion statesNon-expansion statesAdult patientsStudy endpointAdjusted differenceCancer DatabaseMedicaid populationEligible facilitiesPatientsCancerLogistic regression
2020
Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.
Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, Sprenkle P, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaCytoreductive nephrectomyICI eraImproved overall survivalNational Cancer DatabaseOverall survivalIFN eraFuhrman gradeBenefit of CNEfficacy of ICIsClinical T stageCox regression analysisTreatment facility typeRenal cell carcinomaCARMENA trialInterferon eraMultivariable associateN0 diseaseOS benefitProspective reevaluationMedian ageT stageCell carcinomaCancer DatabasePartial nephrectomy
2019
The nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance?
Syed J, Nguyen K, Javier-Desloges J, Leapman M, Raman J, Shuch B. The nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance? Journal Of Clinical Oncology 2019, 37: 485-485. DOI: 10.1200/jco.2019.37.7_suppl.485.Peer-Reviewed Original ResearchUpper tract urothelial cancerMedian overall survivalOverall survivalTumor gradeCox proportional hazards regression modelProportional hazards regression modelsNational Cancer DatabaseKaplan-Meier methodHazards regression modelsHigh-grade tumorsGovernment health insuranceDefinitive surgeryDefinitive therapyOlder patientsPatient demographicsMedian ageWorse survivalUrothelial cancerGrade tumorsAlternative therapiesCancer DatabaseOS differenceRadiation therapyPatientsSurvival analysis
2018
National determinants of active surveillance among patients with clinical stage 1A kidney tumors.
Lu A, Nguyen K, Nolte A, Alimi O, Hsiang W, Ghabili K, Syed J, Shuch B, Leapman M. National determinants of active surveillance among patients with clinical stage 1A kidney tumors. Journal Of Clinical Oncology 2018, 36: 694-694. DOI: 10.1200/jco.2018.36.6_suppl.694.Peer-Reviewed Original ResearchSmall renal massesNational Cancer DatabaseActive surveillanceInitial managementRenal massesCancer DatabaseClinical T1a renal massesMultivariate logistic regression modelFacility-level differencesWest North Central census divisionCancer registry dataT1a renal massesLogistic regression modelsSocio-demographic determinantsDefinitive therapyDefinitive treatmentPatient ageTotal cohortPractice patternsNational utilizationRegistry dataInclusion criteriaCaucasian raceKidney tumorsPatients